Stoke Therapeutics (STOK) Equity Average (2022 - 2025)
Historic Equity Average for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $321.5 million.
- Stoke Therapeutics' Equity Average rose 3542.93% to $321.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.5 million, marking a year-over-year increase of 3542.93%. This contributed to the annual value of $194.3 million for FY2024, which is 1282.53% up from last year.
- Latest data reveals that Stoke Therapeutics reported Equity Average of $321.5 million as of Q3 2025, which was up 3542.93% from $342.5 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Equity Average peaked at $342.5 million during Q2 2025, and registered a low of $150.0 million during Q1 2024.
- In the last 4 years, Stoke Therapeutics' Equity Average had a median value of $208.1 million in 2022 and averaged $225.2 million.
- As far as peak fluctuations go, Stoke Therapeutics' Equity Average crashed by 2477.33% in 2024, and later soared by 9309.15% in 2025.
- Over the past 4 years, Stoke Therapeutics' Equity Average (Quarter) stood at $194.5 million in 2022, then fell by 14.51% to $166.3 million in 2023, then skyrocketed by 38.66% to $230.6 million in 2024, then soared by 39.45% to $321.5 million in 2025.
- Its Equity Average was $321.5 million in Q3 2025, compared to $342.5 million in Q2 2025 and $289.5 million in Q1 2025.